Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event - PubMed (original) (raw)
. 2003 Jul 10;349(2):139-45.
doi: 10.1056/NEJMoa022328.
Affiliations
- PMID: 12853586
- DOI: 10.1056/NEJMoa022328
Free article
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event
Thomas Berger et al. N Engl J Med. 2003.
Free article
Abstract
Background: Most patients with multiple sclerosis initially present with a clinically isolated syndrome. Despite the fact that clinically definite multiple sclerosis will develop in up to 80 percent of these patients, the course of the disease is unpredictable at its onset and requires long-term observation or repeated magnetic resonance imaging (MRI). We investigated whether the presence of serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in patients with a clinically isolated syndrome predicts the interval to conversion to clinically definite multiple sclerosis.
Methods: A total of 103 patients with a clinically isolated syndrome, positive findings on cerebral MRI, and oligoclonal bands in the cerebrospinal fluid were studied. At base line, serum samples were collected to test for anti-MOG and anti-MBP antibodies with Western blot analysis, and the lesions detected by cerebral MRI were quantified. Neurologic examinations for relapse or disease progression (defined as conversion to clinically definite multiple sclerosis) were performed at base line and subsequently every three months.
Results: Patients with anti-MOG and anti-MBP antibodies had relapses more often and earlier than patients without these antibodies. Only 9 of 39 antibody-seronegative patients (23 percent) had a relapse, and the mean (+/-SD) time to relapse was 45.1+/-13.7 months. In contrast, 21 of 22 patients (95 percent) with antibodies against both MOG and MBP had a relapse within a mean of 7.5+/-4.4 months, and 35 of 42 patients (83 percent) with only anti-MOG antibodies had a relapse within 14.6+/-9.6 months (P<0.001 for both comparisons with antibody-seronegative patients). The adjusted hazard ratio for the development of clinically definite multiple sclerosis was 76.5 (95 percent confidence interval, 20.6 to 284.6) among the patients who were seropositive for both antibodies and 31.6 (95 percent confidence interval, 9.5 to 104.5) among the patients who were seropositive only for anti-MOG antibodies, as compared with the seronegative patients.
Conclusions: Analysis of antibodies against MOG and MBP in patients with a clinically isolated syndrome is a rapid, inexpensive, and precise method for the prediction of early conversion to clinically definite multiple sclerosis. This finding may be important for the counseling and care of patients with a first demyelinating event suggestive of multiple sclerosis.
Copyright 2003 Massachusetts Medical Society
Comment in
- Do myelin-directed antibodies predict multiple sclerosis?
Antel JP, Bar-Or A. Antel JP, et al. N Engl J Med. 2003 Jul 10;349(2):107-9. doi: 10.1056/NEJMp030098. N Engl J Med. 2003. PMID: 12853581 No abstract available. - Antimyelin antibodies in multiple sclerosis.
Maguire GA. Maguire GA. N Engl J Med. 2003 Dec 4;349(23):2269-71; author reply 2269-71. doi: 10.1056/NEJM200312043492321. N Engl J Med. 2003. PMID: 14657439 No abstract available. - Antimyelin antibodies in multiple sclerosis.
Mantegazza R. Mantegazza R. N Engl J Med. 2003 Dec 4;349(23):2269-71; author reply 2269-71. N Engl J Med. 2003. PMID: 14663868 No abstract available. - Antimyelin antibodies in multiple sclerosis.
Chaudhuri A, Behan PO. Chaudhuri A, et al. N Engl J Med. 2003 Dec 4;349(23):2269-71; author reply 2269-71. N Engl J Med. 2003. PMID: 14663869 No abstract available.
Similar articles
- Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.
Rauer S, Euler B, Reindl M, Berger T. Rauer S, et al. J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):739-42. doi: 10.1136/jnnp.2005.077784. J Neurol Neurosurg Psychiatry. 2006. PMID: 16705196 Free PMC article. - Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.
Tomassini V, De Giglio L, Reindl M, Russo P, Pestalozza I, Pantano P, Berger T, Pozzilli C. Tomassini V, et al. Mult Scler. 2007 Nov;13(9):1086-94. doi: 10.1177/1352458507077622. Epub 2007 Apr 27. Mult Scler. 2007. PMID: 17468447 - Antimyelin antibodies with no progression to multiple sclerosis.
Pelayo R, Tintoré M, Montalban X, Rovira A, Espejo C, Reindl M, Berger T. Pelayo R, et al. N Engl J Med. 2007 Jan 25;356(4):426-8. doi: 10.1056/NEJMc062467. N Engl J Med. 2007. PMID: 17251547 No abstract available. - The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis.
Kaushansky N, Eisenstein M, Zilkha-Falb R, Ben-Nun A. Kaushansky N, et al. Autoimmun Rev. 2010 Feb;9(4):233-6. doi: 10.1016/j.autrev.2009.08.002. Epub 2009 Aug 13. Autoimmun Rev. 2010. PMID: 19683076 Review. - Antibodies as biological markers for pathophysiological processes in MS.
Reindl M, Khalil M, Berger T. Reindl M, et al. J Neuroimmunol. 2006 Nov;180(1-2):50-62. doi: 10.1016/j.jneuroim.2006.06.028. Epub 2006 Aug 23. J Neuroimmunol. 2006. PMID: 16934337 Review.
Cited by
- Functional Diversity of Neuronal Cell Adhesion and Recognition Molecule L1CAM through Proteolytic Cleavage.
Stoyanova II, Lutz D. Stoyanova II, et al. Cells. 2022 Sep 30;11(19):3085. doi: 10.3390/cells11193085. Cells. 2022. PMID: 36231047 Free PMC article. Review. - Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.
Freedman MS, Metzig C, Kappos L, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink R, Pohl C. Freedman MS, et al. Mult Scler. 2012 Jul;18(7):966-73. doi: 10.1177/1352458511432327. Epub 2011 Dec 19. Mult Scler. 2012. PMID: 22183938 Free PMC article. Clinical Trial. - Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.
Rauer S, Euler B, Reindl M, Berger T. Rauer S, et al. J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):739-42. doi: 10.1136/jnnp.2005.077784. J Neurol Neurosurg Psychiatry. 2006. PMID: 16705196 Free PMC article. - Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis.
Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, Lucas M, Basso AS, Khoury SJ, Lucchinetti CF, Cohen IR, Weiner HL. Quintana FJ, et al. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18889-94. doi: 10.1073/pnas.0806310105. Epub 2008 Nov 21. Proc Natl Acad Sci U S A. 2008. PMID: 19028871 Free PMC article. - Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.
Yukitake M, Sueoka E, Sueoka-Aragane N, Sato A, Ohashi H, Yakushiji Y, Saito M, Osame M, Izumo S, Kuroda Y. Yukitake M, et al. J Neurovirol. 2008 Apr;14(2):130-5. doi: 10.1080/13550280701883840. J Neurovirol. 2008. PMID: 18444084
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous